Refine
Has Fulltext
- yes (6)
Is part of the Bibliography
- yes (6)
Document Type
- Journal article (6)
Language
- English (6)
Keywords
- SARS-CoV-2 (6)
- ceramides (2)
- Calu-3 (1)
- PCLS (1)
- Tamoxifen (1)
- Vero E6 (1)
- acetylsalicylic acid (1)
- acid sphingomyelinase (1)
- antiviral activity (1)
- antivirals (1)
- aspirin (1)
- azapeptide nitriles (1)
- azido-ceramides (1)
- cell line specificity pyridyl indole carboxylates (1)
- cell line-specificity (1)
- ceramidase (1)
- fluoxetine (1)
- peptidomimetics (1)
- phospholipidosis (1)
- precision-cut lung slices (1)
- protease inhibitors (1)
- salicylic acid (1)
- sphingolipids (1)
- viral epidemiology (1)
- viral infection (1)
Institute
- Institut für Virologie und Immunbiologie (6) (remove)
Recently, Tummino et al. reported that 34 compounds, including Chloroquine and Fluoxetine, inhibit SARS-CoV-2 replication by inducing phospholipidosis, although Chloroquine failed to suppress viral replication in Calu-3 cells and patients. In contrast, Fluoxetine represses viral replication in human precision-cut lung slices (PCLS) and Calu-3 cells. Thus, it is unlikely that these compounds have similar mechanisms of action. Here, we analysed a subset of these compounds in the viral replication and phospholipidosis assays using the Calu-3 cells and PCLS as the patient-near system. Trimipramine and Chloroquine induced phospholipidosis but failed to inhibit SARS-CoV-2 replication in Calu-3 cells, which contradicts the reported findings and the proposed mechanism. Fluoxetine, only slightly induced phospholipidosis in Calu-3 cells but reduced viral replication by 2.7 orders of magnitude. Tilorone suppressed viral replication by 1.9 orders of magnitude in Calu-3 cells without causing phospholipidosis. Thus, induction of phospholipidosis is not correlated with the inhibition of SARS-CoV-2, and the compounds act via other mechanisms. However, we show that compounds, such as Amiodarone, Tamoxifen and Tilorone, with antiviral activity on Calu-3 cells, also inhibited viral replication in human PCLS. Our results indicate that antiviral assays against SARS-CoV-2 are cell-line specific. Data from Vero E6 can lead to non-transferable results, underlining the importance of an appropriate cell system for analysing antiviral compounds against SARS-CoV-2. We observed a correlation between the active compounds in Calu-3 cells and PCLS.